Dare Bioscience announced it will receive a payment of $1 million as the latest installment under a grant agreement to advance the development of Dare‘s investigational contraceptive DARE-LARC1 through nonclinical
Dare Bioscience announced it will receive a payment of $1 million as the latest installment under a grant agreement to advance the development of Dare‘s investigational contraceptive DARE-LARC1 through nonclinical
Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Intra-Cellular Therapies (ITCI), 3,244% surge in interest Galera Therapeutics